Cyclosporine in the treatment of azathioprine-induced red cell aplasia following renal transplantation.
Azathioprine, a well-known immunosuppressive agent, is used extensively in renal transplantation. There have been several case reports of pure red cell aplasia induced by this drug following a successful kidney transplant. Previous management of azathioprine-induced red cell aplasia included reduction of azathioprine dose, or treatment with cyclophosphamide. We propose the substitution of cyclosporine for azathioprine, in this clinical setting. Not only does cyclosporine allow recovery of bone marrow function, but it maintains a level of immunosuppression which stabilizes renal function in the post-transplant patient.
Vogt
B
B
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Fivush
B A
BA
D000328:Adult; D001379:Azathioprine / Q000009:adverse effects* / Q000494:pharmacology; D016572:Cyclosporine / Q000627:therapeutic use*; D005260:Female; D006084:Graft Rejection / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000494:pharmacology; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000379:methods; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced / Q000188:drug therapy* / Q000209:etiology*
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D001379:Azathioprine